Cenobamate Works Well for Adults with Epilepsy and ID
This study looked at how well cenobamate, a medication for epilepsy, works in adults with intellectual disability (ID) compared to those without ID.
-
-
Prenatal Antiseizure Medications May Impact Child Development
This study looked at how being exposed to antiseizure medications (ASMs) before birth affects children’s cognitive development from ages 2 to 6.
-
Devices & Neuromodulation | Drug-Resistant Epilepsy | Epilepsy Research Summaries | Genetics | New Studies | Safety & First Aid
Non-Invasive Treatments Show Promise for Drug-Resistant Epilepsy
Researchers studied different non-invasive neurostimulation treatments for people with drug-resistant epilepsy, which is a type of epilepsy that does not respond well to medications.
-
Brain Connectivity Patterns in Children with Self-Limited Epilepsy
Researchers studied brain activity patterns in children with a specific type of epilepsy called self-limited epilepsy with centrotemporal spikes (SeLECTS).
-
Devices & Neuromodulation | Drug-Resistant Epilepsy | Epilepsy Research Summaries | Imaging & EEG | New Studies | Pediatrics
Vagus Nerve Stimulation Shows Promise for Kids with Epilepsy
This study looked at the use of vagus nerve stimulation (VNS) to treat children with drug-resistant epilepsy, meaning their seizures did not respond to standard medications.
-
Understanding Infantile Epileptic Spasms Syndrome Prevalence in India
This study focused on understanding how common infantile epileptic spasms syndrome (IESS) is in India.
-
Boys Face Greater Risks After Neonatal Arterial Ischemic Stroke
Researchers studied how sex affects the severity and outcomes of neonatal arterial ischemic stroke (NAIS) in infants.
-
Children With Cerebral Palsy Face Higher Fracture Risks
Researchers studied children with cerebral palsy (CP) who have more severe movement limitations, classified as GMFCS levels III to V.
-
Many Infants With Genetic Epilepsies May Qualify for New Therapies
Researchers studied the eligibility of infants with genetic epilepsies for a new type of treatment called antisense oligonucleotide therapy.
